Peptide clinical trials: what is being tested in people

  • By Reed Calder
  • Last reviewed Nov 16, 2026
  • Every record opened by hand

The short answer

Many research peptides have no published study in people at all. The trials that do exist are registered on ClinicalTrials.gov, the U.S. registry run by the National Library of Medicine. We read each record, list the ones that test a compound covered on this site, and keep records we couldn’t verify apart. On November 13, 2026, 50 recruiting or about-to-recruit trials passed our checks, and eight records from one sponsor did not. On November 15, 2026, 4 kisspeptin, 3 NAD+, 9 glutathione and 29 oxytocin trials passed too, and on November 16 one gonadorelin and 22 triptorelin trials. 27 more are active but no longer recruiting, and 49 finished since January 2025 with no results posted, counting 19 added on November 15 and 16.

Searching the registry for a peptide returns a long list that mixes tests of the peptide with studies that only measure it in the blood. Here, a trial counts only if the compound is named in a treatment group, and we say who runs it, how big it is and what it tests.

Recruiting now

The list has 118 trials, from thymosin alpha-1 and cerebrolysin to BPC-157, kisspeptin, NAD+, glutathione, oxytocin, gonadorelin, triptorelin, tesamorelin, elamipretide and retatrutide, with sponsor, phase, size and a link to each registry record.

Already running or finished

27 trials are active but no longer recruiting, and 49 more finished since January 2025 with no results posted on the registry. They include Lilly’s retatrutide program and Novo Nordisk’s CagriSema program. You can’t join these; the list shows what is still to be reported.

At a glance

Trials by compound, ClinicalTrials.gov, Nov 13, 2026
Compound Recruiting or about to Active, not recruiting Finished, no results posted
BPC-157 1 0 0
Thymosin beta-4 (NL005) 1 0 1
Tesamorelin 2 0 0
Elamipretide (SS-31) 3 1 0
LUM-201 (MK-677) 4 1 0
GHK-Cu, AHK-Cu and epitalon 1 0 0
Kisspeptin 4 0 1
NAD+ 3 0 2
Glutathione 9 0 5
Oxytocin 29 2 7
Gonadorelin 1 0 0
Triptorelin 22 1 1
Thymosin alpha-1 17 3 3
Cerebrolysin 8 1 1
Retatrutide 1 9 9
Cagrilintide and CagriSema 12 7 18
PT-141 (bremelanotide) 0 1 1
Melanotan 1 (afamelanotide) 0 1 0

How we check a record

We search the registry for each compound under all its names, open every record, and keep it only if the compound is a treatment in the study. Then we check the sponsor, the sites and any named investigator. Records we can’t verify go in their own table. The full method is on the recruiting page.

Questions

What is a peptide clinical trial?

A study that gives a peptide to people under a written plan, to test whether it’s safe or works. Many also give some people a placebo or the usual treatment so the two can be compared.

Where do the trial records come from?

From ClinicalTrials.gov, where the people running a trial register it and update its status (ClinicalTrials.gov, 2026). We link to the record for every trial we list.

Why isn’t every peptide here?

Many peptides sold online have no registered trial at all. The recruiting and in-progress pages each list the compounds where we found none.

Sources

  1. ClinicalTrials.gov. Protocol Registration Data Element Definitions. ClinicalTrials.gov page
  2. ClinicalTrials.gov. Studies that name each compound on this site as an intervention, Nov 13, 2026. Registry

Last reviewed Nov 13, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.